Cover [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock Common stock warrants Statement [Line Items] Statement [Line Items] Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total current assets Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued and other current liabilities Total accrued and other current liabilities Accrued clinical site costs. Accrued clinical site costs Accrued clinical site costs Convertible notes payable accrued interest. Convertible Notes Payable Accrued Interest Convertible note payable and accrued interest - short term Carrying value as of the balance sheet date of insurance loans. Insurance loan payable Derivative Liability, Current Warrant liabilities Liabilities, Current Total current liabilities Notes payable and accrued interest non current. Notes payable and accrued interest non current Convertible note payable and accrued interest - long term Liabilities Total liabilities Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 50,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Common stock, $0.001 par value, 500,000,000 shares authorized; 80,388,330 and 66,442,989 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' (deficit) equity Liabilities and Equity Total liabilities and stockholders' (deficit) equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Litigation Settlement, Expense Settlement expense Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other (income) expenses: Interest Income, Other Interest income Interest Expense Interest expense Interest repayments The increase (decrease) in fair value of convertible debt during the period. Increase (Decrease) In Fair Value Of Convertible Debt Fair value adjustment through earnings Change in fair value of convertible promissory note Fair value adjustment through earnings Derivative, Gain (Loss) on Derivative, Net Change in fair value of warrant liabilities Change in fair value of warrant liability Net Increase or Decrease in the fair value of the earn out liabilities included in earnings in the period. Gain (Loss) on Fair Value of Cash Earnout Liability Change in fair value of earnout cash liability Nonoperating Income (Expense) Total other (income) expenses Net Income (Loss) Attributable to Parent Net loss Net loss Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, Reclassification Adjustment from AOCI for Derecognition, after Tax Change in fair value of convertible note attributed to credit risk Change in fair value of convertible note attributed to credit risk Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss Earnings Per Share [Abstract] Net loss per share: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Diluted Diluted CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY Equity Components [Axis] Equity Component [Domain] Additional Paid-in Capital Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Shares, Outstanding Ending balance ,shares Beginning balance ,shares Represents the value of common stock and warrants issued in a private placement, net of issuance costs. Common Stock And Warrants Issued In Private Placement, Net Of Issuance Costs Common stock and warrants issued, net of issuance costs Represents the number of shares of common stock issued in a private placement of common stock and warrants. Common Stock And Warrants Issued In Private Placement, Number Of Shares Common stock and warrants issued, net of issuance costs (in shares) Shares of common stock sold Represents the value of stock issued for payment of consulting services. Stock Issued For Payment Of Consulting Services Common stock issued for consulting services The number of shares of stock issued for payment of consulting services. Shares Of Stock Issued For Payment Of Consulting Services Common stock issued for consulting services (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock as principal and interest repayment for convertible notes Stock Issued During Period, Shares, Conversion of Convertible Securities Shares issued as repayment of principal and interest for convertible note (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Additional issuance costs in connection with Private Placement APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Stock-based compensation Represents the issuance costs associated with a sale of stock and warrants. Sale Of Stock And Warrants, Issuance Costs Common stock and warrants issued, issuance costs CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation expense Share-based Payment Arrangement, Noncash Expense Stock-based compensation Fair Value Adjustment of Warrants Change in fair value of warrant liabilities Noncash Settlement Expense. Noncash Settlement Expense Non-cash settlement expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Productive Assets Purchase of computer equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from (Repayments of) Notes Payable Repayment of note payable The cash outflow for a repayment of a convertible note. Repayments of convertible note Repayment of convertible note The cash inflow from issuance of insurance loan Proceeds from issuance of insurance loan Proceeds from issuance of insurance loan Proceeds from Warrant Exercises Proceeds from issuance of common stock for exercise of warrant Represents net proceeds (payments) for issuance of common stock and warrants in a private placement, net of issuance costs. Net Proceeds From (Payments For) Issuance Of Common Stock And Warrants In Private Placement, Net Of Issuance Costs Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs Proceeds from sale of common stock Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Issuance of Common Stock Warrants as Offering Costs Issuance of Common Stock Warrants as Offering Costs Issuance of common stock warrants as offering costs Stock Issued Issuance of common stock for settlement of accrued liability Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization Liquidity [Abstract] Liquidity Liquidity [Text Block] Liquidity [Text Block] Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Prepaid Expenses and Other Current Assets The entire disclosure of prepaid expenses and other current assets. Disclosure of Prepaid Expenses and Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued and Other Current Liabilities No definition available. Alvogen Licensing Agreement The disclosure of Alvogen licensing agreement. Alvogen Licensing Agreement [Text Block] Alvogen Licensing Agreement Debt. Debt Disclosure [Text Block] Debt Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Equity Stockholders' Equity Note Disclosure [Text Block] Equity Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Income Taxes Income Tax Disclosure [Text Block] Income Taxes Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Risk And Uncertainties Policy [Text Block] Risk And Uncertainties Policy [Text Block] Certain Risks and Uncertainties Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk and Off-Balance Sheet Risk Revenue [Policy Text Block] Revenue Recognition Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Debt, Policy [Policy Text Block] Convertible Note Payable Share-based Payment Arrangement [Policy Text Block] Stock-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes Earnings Per Share, Policy [Policy Text Block] Loss Per Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Outstanding Shares of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accrued and other current liabilities Convertible Debt [Table Text Block] Summary of Convertible note payable Schedule of Stock by Class [Table] Class of Stock [Line Items] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of activity for warrants Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of fair value determined using the Black-Scholes option-pricing model Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Share-based Payment Arrangement, Cost by Plan [Table Text Block] Summary of recognition of stock-based compensation Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of restricted stock activity Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Fair Value by Liability Class [Domain] Convertible Notes Payable [Member] Convertible notes payable Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of fair value hierarchy Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of measure the convertible note liability No definition available. Schedule Of Warrant Liability Valuation Assumptions Table Text Block Schedule of significant unobservable inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of reconciliation of liabilities Schedule of Related Party Transactions, by Related Party [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Represents the information pertaining to therapeutic product, NRX-101. Therapeutic Product, NRX-101 [Member] NRX-101 Represents the information pertaining to therapeutic product, NRX-100. NRX-100 Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information pertaining to Exclusive, Global - Development, Supply, Marketing & License Agreement. Exclusive, Global - Development, Supply, Marketing & License Agreement [Member] License Agreement Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Represents the information pertaining to Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd [Member] Alvogen Related Party Transaction [Line Items] Number of patients reviewed for both safety and unblinded efficacy data in the clinical trial and advised the Company that no safety concerns were identified. Number Of Patients Reviewed Number of patients reviewed The percentage of standard set for veteran rating team and site raters. Percentage Of Standard Set For Veteran Rating Team And Site Raters Percentage of standard set for veteran rating team and site raters Percentage of threshold congruence achieved with Montgomery Asberg Depression Rating Scale (MADRS), which constitutes the primary efficacy endpoint. Percentage Of Threshold Congruence Achieved Percentage of threshold congruence achieved Threshold number of states covered under the recruitment campaign. Threshold Number Of States Covered Under The Recruitment Campaign Threshold number of states covered under the recruitment campaign Minimum shelf life of supplies. Minimum Shelf Life Of Supplies Minimum shelf life of supplies Term of license agreement from the first commercial sale of Product. License Agreement, Initial Term Initial term Renewal term of license agreement upon request made prior to the expiration of such initial term. License Agreement, Renewal Term Renewal term Number of patients in inpatient trial. Number Of Patients In Inpatient Trial Number of patients in inpatient trial Threshold number of patients' data that would be enough demonstrate preliminary safety and efficacy, as determined by the company. Threshold Number Of Patients Data Enough To Demonstrate Preliminary Safety And Efficacy Threshold number of patients' data that would be enough demonstrate preliminary safety and efficacy Number of patients in randomized prospective trial. Number Of Patients In Randomized Prospective Trial Number of patients in randomized prospective trial Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Cash Cash Class of Warrant or Right, Exercise Price of Warrants or Rights Outstanding at the end (in dollars per share) Outstanding at the beginning (in dollars per share) Warrants, exercise price per share Warrants and Rights Outstanding, Term Warrants expiration term Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Share-based Payment Arrangement, Option [Member] Stock options Restricted stock awards Information related to Public Rights pursuant to UPOs Earnout Shares Information pertaining to earnout shares from exercised Substitute Options and Substitute Warrants. Earnout Shares from exercised Substitute Options and Substitute Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Amount of clinical development expenses paid in advance. Prepaid Clinical Development Expenses Prepaid clinical development expenses Prepaid Insurance Prepaid insurance Other Prepaid Expense, Current Other prepaid expenses Prepaid legal expenses. Prepaid Legal Expenses Prepaid legal expenses Accounts and Other Receivables, Net, Current Other current receivables Accrued Liabilities and Other Liabilities [Abstract] Accrued and other current liabilities: Amount of other expenses incurred but not yet paid , due within one year or the normal operating cycle, if longer. Other Accrued Expenses, Current Other accrued expenses Accrued Employee Benefits, Current Accrued employee expenses Accrued Research And Development Expenses Current Accrued Research And Development Expenses Current Accrued research and development expenses Accrued Professional Fees, Current Professional services Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Alvogen Licensing Agreement Number of business days for payment of equitable royalty in case of reversion license. License Agreement, Minimum Period for Equitable Royalty Payable In Case of Reversion License Equity royalty payable period in case of reversion license Initial cash payment to be received. Initial Cash Payment to be Received First milestone payment to be received Second milestone payments receivable. Second Milestone Payments Receivable Second milestone payment receivable Maximum bonus milestone payments receivable. Maximum Bonus Milestone Payments Receivable Maximum bonus milestone payment receivable Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Information pertaining to the 9% Redeemable Promissory Note. Promissory Note 9% Redeemable [Member] Long-term Debt, Gross Related party loan Par value of the Note Debt Instrument, Face Amount Unsecured promissory note Debt Instrument, Unamortized Discount Debt discount Debt discount Schedule of Short-term Debt [Table] Short-term Debt [Line Items] The amount of principal repaid under debt instrument. Debt Instrument, Repayments of Principal Repayment of Principal Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt before adjustment to fair value of debt Long-Term Debt before Fair Value Adjustments Carrying value of the Note before current period change in fair value The increase (decrease) in fair value of accumulated other comprehensive income from convertible debt during the period. Increase (Decrease) In Fair Value accumulated other comprehensive income Fair value adjustment through accumulated other comprehensive income Long-term Debt Total carrying value of Note Long-term Debt, Current Maturities Convertible note payable - current portion Long-term Debt, Excluding Current Maturities Convertible note payable, net of current portion Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum Maximum Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] GEM Warrant GEM Warrant Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Operating Lease, Expense Warrants Issued During Period Warrants Issued During Period Warrant issued Warrant Exercise Price Warrant Exercise Price Exercise price of warrant Accrued settlement expense. Accrued Settlement Expense Accrued settlement expense Settlement Expense Settlement Expense Additional settlement liability Related Party Transaction, Amounts of Transaction Payment to related party Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Sponsored research agreement. Sponsored Research Agreement [Member] Research and development commitments. Research And Development Commitments Research commitments Relief Therapeutics Collaboration Agreement. Relief Therapeutics Collaboration Agreement [Member] Litigation Status [Axis] Litigation Status [Domain] Relief Therapeutics Lawsuit [Member] Represents information pertaining to Relief Therapeutics lawsuit. Relief Therapeutics Lawsuit Represents information pertaining to Relief Therapeutics Holdings, AG. Relief Therapeutics Holdings, AG The amount of milestone payments receivable under collaborative arrangement. Collaborative Arrangement, Milestone Payments Receivable Milestone payments receivable The amount of royalty payments receivable under collaborative arrangement. Collaborative Arrangement, Royalty Payments Receivable Royalty payments receivable The threshold amount of indemnity claims exceeding which, the company is not liable to pay Collaborative Arrangement, Threshold Liability for Indemnity Claims Indemnity claims he threshold amount of indemnity obligations on breach of representations and warranties, exceeding which, the company is not liable to pay. Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Representations and Warranties Representations and Warranties The threshold amount of indemnity obligations on breach of covenants and other agreements, exceeding which, the company is not liable to pay. Collaborative Arrangement, Threshold Indemnity Obligation for Breach of Covenants and Other Agreements Covenants and Other Agreements GEM Share Subscription Facility Agreement. GEM Share Subscription Facility Agreement Expiration term for issued warrants. Warrants Expiration Term Expiration term of warrants Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Number of shares issued upon exercise of warrants Sale of Stock [Axis] Sale of Stock [Domain] Securities Purchase Agreement on June 6, 2023 aka "June Investors." Securities Purchase Agreement June Investors Represents information pertaining to H.C. Wainwright & Co. LLC. H.C. Wainwright & Co. LLC The percentage of cash fee on gross proceeds received, paid to the placement agent under the securities purchase agreement. Securities Purchase Agreement, Placement Agent Fee Percentage Securities purchase agreement, placement agent fee percentage Payments of Stock Issuance Costs Less: transaction costs and advisory fees allocated to NRXP equity Represents the information pertaining to Substitute Warrants. Substitute Warrants Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Represents the information pertaining to merger agreement with merger sub and NeuroRx. Merger agreement Represents the information pertaining to stockholders of NeuroRx. Stockholders of NeuroRx Stockholders' Equity Note, Stock Split, Conversion Ratio Exchange Ratio Represents the information pertaining to Public Warrants. Public Warrants Class of Warrant or Right, Outstanding Outstanding at the end Outstanding at the beginning Number of outstanding warrants Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares per warrant Represents the class of warrant or right exercised during the period. Warrants Exercised During Period Exercised Warrants exercised during period Class of Warrant or Right [Table] Represents the information pertaining to June Investor Amended Warrants. June Investor Amended Warrants [Member] Measurement Input Type [Axis] Measurement Input Type [Domain] Stock price on valuation date Exercise price per share Expected life Volatility Risk-free rate Dividend yield Measurement input using fair value of share. Fair value of warrants Minimum Minimum Class of Warrant or Right [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Expected term (years) Fair value portion of warrants. Warrants Fair Value Disclosure Warrants fair value disclosure Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input Warrants and rights outstanding, measurement input No definition available. Class of Warrant or Right, Number [Abstract] Total Warrants Class of warrant or right issued. Class of Warrant or Right, Issued Issued No definition available. Class of Warrant or Right, Weighted Average Remaining Term [Abstract] Weighted Average Remaining Term Represents the weighted average remaining contractual term of warrants. Class Of Warrant Or Right Weighted Average Remaining Contractual Term 2 Outstanding Represents the weighted average remaining contractual term of warrants issued. Class of Warrant or Rights, Grant In Period Weighted Average Remaining Contractual Term Issued (in years) No definition available. Class of Warrant or Right, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Represents the weighted average exercise price of warrants issued. Class of Warrant or Right Exercise Price of Warrants or Rights Issued Issued (in dollars per share) Plan Name [Axis] Plan Name [Domain] Two Thousand Sixteen Omnibus Plan [Member] Two Thousand Sixteen Omnibus Plan [Member] 2016 Omnibus Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the end (in shares) Outstanding at the beginning (in shares) Options to purchase shares of common Stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end (in dollars per share) Outstanding at the beginning (in dollars per share) Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Volatility rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free rate of interest, minimum Risk-free rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free rate of interest, maximum Risk-free rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Award Type [Axis] Award Type [Domain] Stock Options [Member] Stock Options Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Exercise price minimum Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Exercise price maximum Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options vested and exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Options vested and exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining remaining term (in years) Weighted average remaining contractual term for option awards outstanding during the period. Share Based Compensation Arrangement Options Outstanding, Weighted Average Remaining Contractual Term 2 Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at the end (in dollars) Outstanding at the beginning (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average period Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and administrative Research and development Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expense Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance, beginning of period Balance, end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Grant date fair value, beginning of period End of period Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation, restricted stock Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring basis Level 1 Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Money Market Account Liabilities, Fair Value Disclosure [Abstract] Liabilities: Convertible Debt, Fair Value Disclosures Convertible note payable (Note 7) Total carrying value of Note Time to expiration Measurement input using market interest rate. Note market interest rate Measurement input using equity volatility. Equity volatility Measurement input using volume volatility. Volume volatility Probability of default Debt Instrument, Periodic Payment, Principal Repayment of Principal Convertible Debt Carrying value of the Note before current period change in fair value Convertible Debt, Current Convertible note payable - current portion Convertible Debt, Noncurrent Convertible note payable, net of current portion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at the end Balance at the beginning Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Gain upon re-measurement Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Income Tax Expense (Benefit) Provision or benefit for income tax expense Agreement [Axis] Agreement [Axis] Agreement [Domain] Agreement [Domain] Glytech Agreement [Member] Glytech Agreement [Member] Information pertaining to the PillTracker SOW. PillTracker SOW Related Party [Axis] Related Party [Domain] Information related to the former CEO. Former Chief Executive Officer [Member] Former CEO Chief Executive Officer Son [Member] Chief Executive Officer Son [Member] Related Party [Member] The minimum value of equity required for the transfer of assets from related parties to the Company. Minimum Equity Value Required For Transfer Of Assets Minimum equity required for transfer of Excluded Technology Number of consecutive trading days required of minimum equity met for the transfer of assets from a related party to the Company. Minimum Equity Required For Transfer Of Assets From Related Party, Number of Consecutive Trading Days Number of consecutive trading days Number of trading days required of minimum equity met for the transfer of assets from a related party to the Company. Minimum Equity Required For Transfer Of Assets From Related Party, Number of Trading Days Number of trading days Threshold aggregate liquidity of the related party. License Agreement, Threshold Aggregate Liquidity Threshold aggregate liquidity of the related party The amount of consulting fee payable per month under related party transactions. Related Party Transaction, Consulting Fee Payable Per Month Consulting fee payable per month The amount of performance-based annual bonus with a minimum target payable under related party transaction. Related Party Transactions, Performance Based Annual Bonus Minimum Target Performance based annual bonus minimum target Number of shares shall have restrictions removed on new drug application date. Number of Shares, Restrictions Removed on New Drug Application Date Number of shares, restrictions removed on new drug application date Number of shares will have restrictions removed on new drug approval date. Number of Shares, Restrictions Removed on New Drug Approval Date Number of shares, restrictions removed on new drug approval date Accounts Payable Accounts payable due to related parties Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items]